The company specialising in pharmaceutical synthesis and specialty ingredients has inaugurated a brand new 34,000-square-metre science platform.
Located close to Paris, SEQENS’Lab has assembled the group’s key skills and expertise, such as: organic chemistry development at the forefront of the latest innovations, two referring laboratories in Physics & Solid-State Chemistry as well as in Process Safety, kinetic and thermodynamic simulation tools, large batch manufacturing capabilities for preclinical and clinical studies, all in an environment that adheres to cGMP.
According to Seqens, the new R&D centre has “innovative means for developing future processes, particularly in flow chemistry, that are more productive and energy-efficient and have minimal environmental impact.” Innovative SMEs and start-ups that are specialised in analytical services and CROs will be hosted at SEQENS’Lab, providing the company’s customers with an access to complementary skills in one place.
The company also aims to facilitate collaboration amongst its teams in a modern and appealing location, designed for carrying out their customers’ projects more effectively and efficiently. Three main principles make up its definition:
Create a dynamic ecosystem facilitating collaboration between Seqens teams, innovative SMEs and academic partners;
Gather in one place multidisciplinary teams with the skills needed to complete our customers’ projects;
Create an attractive and modern space, a reference point and a showcase for our customers.
“The SEQENS’Lab is dedicated to our customers and accelerating their projects. It is also dedicated to our teams, this centre is theirs too. Seqens currently has a world-class innovation and development centre,” explained Pierre Luzeau, Seqens group CEO.